NasdaqGS - Delayed Quote • USD
AN2 Therapeutics, Inc. (ANTX)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.62 | -0.63 | -2.57 | -2.45 |
| Low Estimate | -0.67 | -0.73 | -3.05 | -2.85 |
| High Estimate | -0.56 | -0.54 | -2.19 | -1.83 |
| Year Ago EPS | -0.79 | -0.81 | -2.74 | -2.57 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.68 | -0.85 | -0.63 | -0.75 |
| EPS Actual | -0.79 | -0.81 | -0.65 | -0.57 |
| Difference | -0.11 | 0.04 | -0.02 | 0.18 |
| Surprise % | -16.20% | 4.70% | -3.20% | 24.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.62 | -0.63 | -2.57 | -2.45 |
| 7 Days Ago | -0.62 | -0.63 | -2.57 | -2.45 |
| 30 Days Ago | -0.76 | -0.75 | -2.89 | -2.94 |
| 60 Days Ago | -0.76 | -0.75 | -2.89 | -2.97 |
| 90 Days Ago | -0.76 | -0.75 | -3.1 | -3.28 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 4 | 4 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ANTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 21.50% | -- | -- | 6.50% |
| Next Qtr. | 22.20% | -- | -- | 12.00% |
| Current Year | 6.20% | -- | -- | 5.30% |
| Next Year | 4.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | JMP Securities: Market Perform to Market Outperform | 4/2/2024 |
| Reiterates | Oppenheimer: Perform to Perform | 4/1/2024 |
| Downgrade | Leerink Partners: Outperform to Market Perform | 2/13/2024 |
| Downgrade | Evercore ISI Group: Outperform to In-Line | 2/12/2024 |
| Downgrade | Oppenheimer: Outperform to Perform | 2/12/2024 |
| Downgrade | JMP Securities: Market Outperform to Market Perform | 2/12/2024 |
Related Tickers
ELYM Eliem Therapeutics, Inc.
3.9800
+17.40%
TRML Tourmaline Bio, Inc.
15.68
-2.00%
AMLX Amylyx Pharmaceuticals, Inc.
1.7600
-1.12%
AADI Aadi Bioscience, Inc.
1.7500
+4.17%
CMPX Compass Therapeutics, Inc.
1.4500
-2.03%
VTYX Ventyx Biosciences, Inc.
3.9300
-3.20%
VINC Vincerx Pharma, Inc.
0.7300
-18.59%
CALC CalciMedica, Inc.
5.45
-0.18%
SPRB Spruce Biosciences, Inc.
0.7000
-0.14%
IVA Inventiva S.A.
3.2500
+2.85%